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Introduction
According to WHO statistics, headache is one of the most frequent disabling 
conditions encountered in medicine. Migraine is the most common headache with 
vascular origin, which affects about 18% of women and 6.5% of men. More than 
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Migraine is known as one of the most disabling types of headache. Among the 
variety of theories to explain mechanism of migraine, role of serum magnesium 
is of great importance. Serum magnesium, as a pathogenesis factor, was 
considerably lower in patients with migraine. We established this study to see if 
serum ionized magnesium, not its total serum level, was different in migraineurs 
from normal individuals.
Materials & Methods
In this case control study, all participants were recruited from Neurology Clinic 
of Imam Hossein Hospital, Tehran, Iran. Ninety-six people were entered in the 
study, 48 for each of case and control groups. The two groups were matched 
by age and sex. Migrainous patients were selected according to the criteria 
of International Headache Society. Various characteristics of headache were 
recorded based on patients’ report. Controls had no history of migraine or any 
significant chronic headaches. Serum ionized magnesium level was measured in 
both of the case and control groups and the results were compared to each other. 
P value of <0.05 was considered as significant. 
Results
Case group consisted of 13 males, 35 females, and control group included 14 
males, as well as 34 females. Mean age was 33.47± 10.32 yr for case and 30.45 
±7.12 yr for control group. Twenty-eight patients described the intensity of their 
headaches as moderate; 15 patients had severe and the 5 remainders had only 
mild headaches. Mean serum level of ionized Mg was 1.16± 0.08 in case group 
and 1.13± 0.11 in control group of no significant difference (P >0.05).
Conclusion
Serum ionized magnesium, which is the active form of this ion, was not 
significantly different in migraineurs and those without migraine. This may 
propose a revision regarding pathogenesis of migraine and question the role of 
magnesium in this type of headache.
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90% of the migraineurs state a relative inability to do 
their daily activity and about 53% require complete 
resting during an attack (1). 
Regarding the high incidence and prevalence of migraine 
and its disabling nature, it seems crucial to detect the exact 
mechanism. This can guide us through better plans for 
disease management. Significance of magnesium (Mg) 
in pathogenesis of migraine has been credited in some 
studies and refused in others. Magnesium deficiency 
is much more prevalent in migraine sufferers than in 
healthy controls (2). Besides, based on insufficient data, 
magnesium has been used for migraine prophylaxis and 
treatment of acute migraine in clinic (3). 
This study was set up to challenge the role of Mg in 
migraine by measuring serum ionized Mg level, which is 
the active form of this ion, in migraine patients referred 
to Imam Hossein Hospital, Tehran, Iran and to compare 
the values with normal population.
Materials & Methods
In this case control study, considering the parameters of 
P=0.50, α=0.05, d=0.10, the size of sample groups was 
estimated at least 96 people totally, 48 people for each 
of the case and control groups. The case group included 
48 migraine patients recruited from Neurology Clinic 
of Imam Hossein Hospital, Tehran, Iran. In addition, 48 
individuals were randomly selected from patients visited 
in hospital neurology clinics and entered the study 
as control group. In past medical history and physical 
examination, none of the participants of control group 
had migraine or any major neurologic problems. The 
two groups were matched by age and sex.
All aspects of the study were explained to the participants 
and they filled a consent form. The study was approved 
by the Ethics Committee of Imam Hossein Hospital.
Inclusion criteria for the case group were as follows: 
definite migraine diagnosis on the basis of International 
Headache Society (IHS) criteria (4); at least two 
monthly episodes of headache; a history of headache 
during the last 3 months; no headaches at the time of 
blood sampling or within the previous two days; fasting 
for at least 10 hours before the blood sample was 
taken; no history of migraine prophylactic drugs or Mg 
supplements consumption; and no history of underlying 
systemic diseases. 
Those patients fulfilled the inclusion criteria, were 
examined carefully and essential lab data (including 
CBC and serum electrolytes) were requested. 
In addition to the topographic information, obtained 
from both groups, participants of the case group also 
filled a questionnaire containing most of the required 
parameters related to migraine. Patients filled the 
questionnaire two times; once at the first visit and next 
at the time the laboratory results were ready. Items of 
the questionnaire included: type of migraine (with or 
without aura), type of aura (visual, sensory, motor, 
language), location of the headache, presence or absence 
of orbital pain, accompanying symptoms (photophobia, 
phonophobia, nausea and vomiting), family history of 
migraine and severity of headaches. Severity of headache 
was recorded as a quantitative score using visual analog 
scale (VAS) which classifies headaches as mild (0-3), 
moderate (4-6), and severe (7-10). 
Serum ionized Mg level was measured in both case 
and control groups using Ion Selective Electrode (ISE) 
method which eliminates the effect of serum free calcium 
levels on measured serum ionized Mg (5). Because 
depletion of Mg from hemolyzed red blood cells could 
falsely increase serum Mg level and disturb the results, 
hemolysis of the samples was prevented. 
Data were analyzed using SPSS version 17 software 
(Chicago, IL, USA). X2 and t-test were applied to 
analyze and compare data. P value<0.05 was determined 
as significant.
Results
Each of the case and control groups contained 48 people. 
Distribution of age and sex was matched in two groups 
(P value < 0.05 for both items). Mean age was 33.47± 
10.32 yr for case and 30.45 ±7.12 yr for control group. 
Case group consisted of 13 males, 35 females, and 
control group included 14 males as well as 34 females. 
Most of the migraineurs were female (35 people) and 41 
(85.5%) had migraine without aura. Only seven patients 
(14.5%) experienced auras of which 5 were purely visual 
and 2 were a combination of visual and sensory type. 
Thirty-three patients had bilateral and 15 had unilateral 
headaches. Majority of patients reported more than one 
region for their headaches. Frontal and temporal were 
dominant locations in most cases (83.3% and 77%). 
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Headache in occipital and vertex regions were next in 
frequency. Orbital pain, which is a common presentation 
of migraine, was reported by 34 patients. 
Most common symptoms accompanying headaches were 
phonophobia (44 people; 91.6%) and photophobia (41 
people; 85.4%). Frequency of migraine accompanying 
symptoms is shown in Table 1. 
Table 1. Frequency of Symptoms Accompanying 
Headache. Each patient May Have More Than One 
Accompanying Symptom
  Percentage   Number   Symptom
85.441   Photophobia
    91.644   Phonophobia
    12.56   Osmophobia
66.6    32   Nausea
20.8    10   Vomiting
Twenty-eight patients (58.3%) had a history of the 
disease in their first degree relatives while 20 patients 
(41.7%) had no family history of migraine.
Using VAS, 28 patients described the intensity of their 
headaches as moderate, 15 patients had severe and the 5 
remainders had mild headaches.
Mean serum level of ionized Mg was 1.16± 0.08 mEq/L 
in case group and 1.13± 0.11 mEq/L in control group. 
There was no significant difference on serum ionized 
Mg level between the two groups (P value > 0.05).
Discussion
Migraine seems to have a complex pathogenesis. To 
explain the mechanism of migraine several theories have 
been suggested. A phosphorylation oxidative defect, 
malfunction of intraneuronal voltage gated calcium 
channels, intracellular magnesium (Mg) deficiency or a 
combination of these may make the cells susceptible to 
spontaneous depolarization (6).
Serum Mg has an influence over the serotonin 
receptors, synthesis and release of nitrous oxide, 
N-Methyl-D-aspartate (NMDA) receptor and some 
other neurotransmitters (7). Serum Mg level is lower in 
migraineurs. 
Sun and colleagues evaluated the role of Mg as an 
important intracellular element. They showed that Mg 
interacted with serotonin receptors and reduced the 
severity of migraine headache. They also showed that 
Mg took part in diffuse cortical depression, altered the 
release of some neurotransmitters and enhanced platelet 
aggregation. They suggested that prophylactic use of 
oral Mg or therapeutic administration of intravenous Mg 
during an episode of headache was a useful approach and 
reduced migraine attacks (8). Altura et al. stressed that 
recalcitrant headaches might be relieved by intravenous 
Mg sulfate (9). 
In menstrual migraine, ionized Mg level is decreased 
and the ratio of Ca/Mg level is increased. Therefore, 
serum Mg level may have a role in pathogenesis of 
menstrual migraine (10). Mishima et al. and Aloisi et al. 
also reported a lower serum Mg in migrainous patients 
(11, 12). Trauninger and colleagues concluded that there 
was no significant difference between migraineurs and 
normal individuals in both serum and urine Mg level 
although the average serum Mg was lower in patients 
with migraine (13).
According to results of our study, serum level of ionized 
Mg, which is the active form of magnesium, was not 
significantly different in migraineurs from those without 
migraine. This is in contrast with the results of the study 
by Mauskop et al. (9). However, most of the other studies 
mentioned above had emphasized the role of total serum 
Mg. In this study ionized Mg level was measured 
instead of its total amount. This may propose a revision 
regarding pathogenesis of migraine and question the role 
of this ion in migraine. 
In conclusion, it seems that measurement of total 
serum Mg level is not sufficient to explain migraine 
mechanism, because only the ionized form of Mg has 
biologic effectiveness. Further investigation may be 
required in this issue.
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